noom med glp 1 offers cut-price compounded GLP-1 drug for obesity Noom Launches GLP-1 Microdosing for

GLP-1s are primarily for treating type 2 diabetes, obesity, cardiovascular disease, and sleep apnea

A handful of glucagon-like peptide-1 (GLP-1) agonists have received US Food and Drug Administration (FDA) approval for obesity treatmentincluding liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound)while others, like exenatide (Byetta, Bydureon), liraglutide (Victoza), semaglutide (Ozempic, Rybelsus), and tirzepatide (again, known as Mounjaro for the diabetes indication), are indicated for type 2 diabetes

Its easy to use and it works

This is why I didnt recommend it to my uncle

This helps this podcast, get out to the people who need it